X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (143) 143
male (100) 100
index medicus (85) 85
urology (83) 83
urology & nephrology (75) 75
cancer (71) 71
middle aged (68) 68
aged (63) 63
female (61) 61
kidney neoplasms - pathology (47) 47
oncology (46) 46
prostate cancer (41) 41
adult (37) 37
carcinoma, renal cell - pathology (37) 37
renal cell carcinoma (37) 37
prognosis (36) 36
carcinoma, renal cell (35) 35
kidney neoplasms - therapy (33) 33
carcinoma, renal cell - therapy (31) 31
treatment outcome (29) 29
aged, 80 and over (28) 28
metastasis (28) 28
diagnosis (27) 27
neoplasm staging (27) 27
survival (26) 26
care and treatment (24) 24
carcinoma, renal cell - drug therapy (21) 21
analysis (20) 20
antibodies, monoclonal - therapeutic use (20) 20
kidney neoplasms - drug therapy (20) 20
kidney neoplasms - surgery (19) 19
nephrectomy (19) 19
risk factors (19) 19
men (18) 18
neoplasm metastasis (18) 18
survival analysis (18) 18
biopsy (17) 17
carcinoma, renal cell - surgery (17) 17
interferon-alpha (17) 17
antineoplastic agents - therapeutic use (16) 16
carcinoma (16) 16
kidney neoplasms - mortality (16) 16
carcinoma, renal cell - diagnostic imaging (15) 15
carcinoma, renal cell - mortality (15) 15
carcinoma, renal cell - secondary (15) 15
medical colleges (15) 15
sorafenib (15) 15
tumors (15) 15
animals (14) 14
chemotherapy (14) 14
kidney neoplasms - diagnostic imaging (14) 14
disease-free survival (13) 13
follow-up studies (13) 13
immunotherapy (13) 13
kidney (13) 13
prostatic neoplasms - diagnosis (13) 13
prostatic neoplasms - pathology (13) 13
radioimmunotherapy (13) 13
therapy (13) 13
time factors (13) 13
urology and nephrology (13) 13
antineoplastic combined chemotherapy protocols - therapeutic use (12) 12
life sciences (12) 12
research (12) 12
retrospective studies (12) 12
adolescent (11) 11
carcinoma, renal cell - immunology (11) 11
carcinoma, renal cell - metabolism (11) 11
kidney neoplasms - immunology (11) 11
kidney neoplasms - metabolism (11) 11
medical research (11) 11
nephrectomy - methods (11) 11
radical nephrectomy (11) 11
survival rate (11) 11
antigens, neoplasm - urine (10) 10
carcinoma, renal cell - diagnosis (10) 10
double-blind (10) 10
endocrinology & metabolism (10) 10
mice (10) 10
predictive value of tests (10) 10
prostate-specific antigen - blood (10) 10
prostatic neoplasms - urine (10) 10
radionuclide imaging (10) 10
sunitinib (10) 10
urine (10) 10
abridged index medicus (9) 9
article (9) 9
child (9) 9
disease progression (9) 9
expression (9) 9
g250 (9) 9
hematology, oncology and palliative medicine (9) 9
kidney neoplasms - diagnosis (9) 9
monoclonal antibodies (9) 9
prospective studies (9) 9
prostatic neoplasms (9) 9
radical prostatectomy (9) 9
abiraterone acetate (8) 8
bevacizumab (8) 8
carbonic anhydrase ix (8) 8
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Tijdschrift voor Urologie, ISSN 2211-3037, 11/2018, Volume 8, Issue S3, pp. 2 - 27
Biochemisch recidiverende prostaatkanker (BCR) is de belangrijkste indicatie voor het uitvoeren van prostaatspecifiek membraan antigeen PET/CT (PSMA PET/CT).... 
Medicine & Public Health | Urology
Journal Article
European Urology, ISSN 0302-2838, 2010, Volume 58, Issue 3, pp. 398 - 406
Journal Article
Lancet Oncology, ISSN 1470-2045, 2015, Volume 16, Issue 2, pp. 152 - 160
Journal Article
European Urology Supplements, ISSN 1569-9056, 11/2018, Volume 17, Issue 14, pp. e2925 - e2926
Journal Article
European Urology Supplements, ISSN 1569-9056, 11/2018, Volume 17, Issue 14, pp. e2925 - e2926
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2010, Volume 362, Issue 13, pp. 1192 - 1202
Dutasteride, an inhibitor of 5α-reductase in the prostate, was tested in a large, randomized trial to determine its ability to prevent prostate cancer. Over... 
MODELING APPROACH | MEDICINE, GENERAL & INTERNAL | DESIGN | THERAPY | 5-ALPHA-REDUCTASE INHIBITOR DUTASTERIDE | SENSITIVITY | FINASTERIDE | GRADE | HYPERPLASIA | PROGRESSION | PREVENTION TRIAL | Enzyme Inhibitors - adverse effects | Prostatic Neoplasms - pathology | Prostatic Hyperplasia - pathology | Double-Blind Method | Erectile Dysfunction - chemically induced | Humans | Middle Aged | 5-alpha Reductase Inhibitors | Male | Risk | Treatment Outcome | Azasteroids - therapeutic use | Enzyme Inhibitors - therapeutic use | Prostate-Specific Antigen - blood | Azasteroids - adverse effects | Prostate - pathology | Prostatic Neoplasms - genetics | Biopsy | Protein Isoforms | Dutasteride | Aged | Prostatic Neoplasms - prevention & control | Prostatic Hyperplasia - drug therapy | Heart Failure - chemically induced | Usage | Diagnosis | Health aspects | Prostate cancer | Risk factors | Patient safety | Age | Men | Tumors | Prostate-Specific Antigen | Erectile Dysfunction | Enzyme Inhibitors | Testosterone 5-alpha-Reductase | Prostatic Hyperplasia | Life Sciences | Prostatic Neoplasms | Azasteroids | Heart Failure | Prostate | Cancer | pathology | genetics | Urologi och njurmedicin | chemically induced | drug therapy | prevention & control | blood | adverse effects | Cancer and Oncology | Urology and Nephrology | therapeutic use | Cancer och onkologi
Journal Article
European Urology Supplements, ISSN 1569-9056, 10/2019, Volume 18, Issue 8, pp. e3045 - e3045
Journal Article